Lifileucel (melanoma; EU 2025), TILVANCE-301 first-line, NSCLC and cervical trials; next-gen PD-1-inactivated TIL (IOV-4001).
Pages like this
not linked directly; found by shared links- PersonAmod A. Sarnaik
Shares C-144-01, C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy.
- PersonSteven A. Rosenberg
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
- PairingPD-1 failure → TIL therapy
Shares Lifileucel, TIL therapy, Melanoma.
- Key paperRohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Manufacturing cost and time for living and radioactive medicines.
- PersonJohn Haanen
Shares Select patients for cell therapy by whether their tumour holds reactive T cells, Lifileucel, TIL therapy, Melanoma.
- ProductAldesleukin (high-dose IL-2)
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, TIL therapy, Melanoma.
- IdeaAn open interoperability standard for closed automated cell-processing machines
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines.
- IdeaDigital batch records and AI process control to halve cell therapy batch failures
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines.